Bangladesh, Nov. 17 -- Renata PLC has expanded its European footprint by launching its Parkinson's disease drug in the Netherlands, marking a fresh milestone for the Bangladeshi pharmaceutical company in its pursuit of highly regulated overseas markets.

Advertisement The company has launched Amantadine HCl 100 mg hard capsules in the Dutch market, targeting patients requiring symptomatic treatment for Parkinson's disease, according to a stock exchange disclosure on Tuesday.

The medicine is being manufactured at Renata's EU-GMP-approved Rajendrapur General Facility and supplied in blister packs containing 56 capsules.

The latest launch strengthens Renata's presence in Europe, where stringent regulatory requirements and quality standard...